Singh, Jasvinder A. http://orcid.org/0000-0003-3485-0006
Cleveland, John D.
Funding for this research was provided by:
research funds from the Division of Rheumatology at the University of Alabama at Birmingham (No number)
the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA (No number)
Article History
Received: 22 March 2018
Accepted: 9 July 2018
First Online: 3 August 2018
Ethics approval and consent to participate
: The UAB’s institutional review board approved this study, and all investigations were conducted in conformity with ethical principles of research. The institutional review board waived the need for informed consent for this database study.
: Not required.
: JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan, WebMD, UBM LLC, and the American College of Rheumatology (ACR). JAS serves as the principal investigator for an investigator-initiated study funded by Horizon through a grant to Dinora, Inc., a 501 (c)(3) entity. JAS is a member of the executive board of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the ACR Annual Meeting Planning Committee; chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JDC declares that he has no competing interests. The authors declare that they have no non-financial competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.